Jia Weihong, Yang Dongcai
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Northwest University, Xi'an No. 3 Hospital, Xi'an, China.
Postepy Dermatol Alergol. 2023 Aug;40(4):548-553. doi: 10.5114/ada.2023.129458. Epub 2023 Sep 1.
Asthma is a pulmonary disease and its pathogenesis is involved with immune cells and related signalling pathways. Alpha-alumina is material for therapy applications and mucus adhesion promoting protein is cell-surface protein. Vasoactive intestinal peptide (VIP) exerts immunomodulation. Therefore, the drug delivery system and target binding molecule could be applicable for treatment of asthma.
VIP-MapA-α-alumina was administered to asthmatic mice. Then, eosinophil percentage, IgE, IL-4, IL-5, and IL-13 levels, GATA3, and MUC5AC gene expression, ROS and lung histopathology were studied.
Eosinophil percentage, IgE, IL-4, IL-5, IL-13, and ROS levels, expression of GATA3 and MUC5AC genes, goblet cell hyperplasia, mucus hyper-production, perivascular and peribronchial inflammation were decreased in VIP and VIP-MapA treated groups and treatment with VIP-MapA has a stronger effect than VIP alone.
The delivery system of VIP carrying to the lung with the use of MapA as an adhesion molecule, could easily carry VIP and led to penetration of this component to the mucus and reach bronchial cells and present an effective, strong, and long-acting effect on therapy of asthma.
哮喘是一种肺部疾病,其发病机制与免疫细胞及相关信号通路有关。α-氧化铝是一种治疗应用材料,黏液黏附促进蛋白是一种细胞表面蛋白。血管活性肠肽(VIP)具有免疫调节作用。因此,药物递送系统和靶向结合分子可用于哮喘治疗。
将VIP-MapA-α-氧化铝给予哮喘小鼠。然后,研究嗜酸性粒细胞百分比、免疫球蛋白E(IgE)、白细胞介素-4(IL-4)、白细胞介素-5(IL-5)和白细胞介素-13水平、GATA3和黏蛋白5AC(MUC5AC)基因表达、活性氧(ROS)及肺组织病理学。
VIP组和VIP-MapA组嗜酸性粒细胞百分比、IgE、IL-4、IL-5、IL-13及ROS水平、GATA3和MUC5AC基因表达、杯状细胞增生、黏液过度产生、血管周围和支气管周围炎症均降低,且VIP-MapA治疗效果比单独使用VIP更强。
以MapA作为黏附分子将VIP递送至肺部的递送系统,能够轻松携带VIP并使其穿透黏液到达支气管细胞,对哮喘治疗呈现出有效、强效且长效的作用。